WARF: P06398US

  • Assigned to WARF as biological material.

Clonal Lines of Human Cervical Epithelial Cells That Harbor Human Papillomavirus Type 16


Paul Lambert, Saewha Jeon

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in two human cervical epithelial cell populations that stably contain HPV16.
OVERVIEWHuman papillomaviruses (HPVs) are the most common sexually transmitted pathogens. These small DNA viruses are associated with almost all cervical cancers and about 20 percent of head and neck cancers.
THE INVENTIONUW-Madison researchers have developed clonal lines of human cervical epithelial cells that stably harbor the double-stranded, circular human papillomavirus type 16 (HPV16) genome. One set of cell lines contains HPV16 DNA as an extrachromosomal nuclear plasmid. These cell lines are useful for studying aspects of the viral life cycle, including host and viral requirements for viral DNA replication and transcription. The other cell lines comprise HPV16 DNA integrated into their genome, similar to what is observed in cervical cancer. Both sets of cell lines were subcloned from the same parent population, and therefore are closely matched.
  • Studying the role of integration in viral-associated cancers
  • Provides the first human cervical epithelial cell population that stably contains HPV16 as a nuclear plasmid
For More Information About the Inventors
Contact Information
For current licensing status, please contact Mark Staudt at or 608-960-9845.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.